A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis

• Published in: The Journal of dermatological treatment Vol. 35; no. 1; p. 2366535
• Main Authors: Wang, Guanghan, Hu, Xiaojing, Han, Shixin, Zhou, Meijuan
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis Group 01.12.2024
• Subjects: Antibodies, Monoclonal, Humanized - adverse effects; bullous pemphigoid; Dermatologic Agents - adverse effects; Humans; Male; Middle Aged; Minocycline - adverse effects; Niacinamide - adverse effects; Niacinamide - analogs & derivatives; Niacinamide - therapeutic use; Pemphigoid, Bullous - chemically induced; Pemphigoid, Bullous - diagnosis; Pemphigoid, Bullous - drug therapy; Pemphigoid, Bullous - pathology; psoriasis; Psoriasis - chemically induced; Psoriasis - drug therapy; Secukinumab; Treatment Outcome; Secukinumab; bullous pemphigoid; psoriasis
• ISSN: 0954-6634; 1471-1753; 1471-1753
• DOI: 10.1080/09546634.2024.2366535

Bullous pemphigoid induced by secukinumab in treatment of psoriasis is rare. We report a 49-year-old man with psoriasis who developed bullous pemphigoid during treatment with secukinumab. Scattered tense vesicles with itching appeared all over the body after the fourth treatment. Bullous pemphigoid was confirmed by pathological examination and direct immunofluorescence. The patient was treated with topical corticosteroids, oral nicotinamide and minocycline hydrochloride. The lesions of bullous pemphigoid improved significantly after 7 days of treatment. Bullous pemphigoid is a rare adverse event following administration of secukinumab.